BPA
ASBPW

Beacon Pointe Advisors’s Aspire Biopharma Warrant ASBPW Stock Holding History

Beacon Pointe Advisors’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$400 Hold
20,000
– – ﹤0.01% 1915
2026
Q1 		$332 Hold
20,000
– – ﹤0.01% 1832
2025
Q4 		$330 Buy
+20,000
New +$616 ﹤0.01% 1504

Other funds holding ASBPW

SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Beacon Pointe Advisors's ASBPW Position: Q2 2026 in Review

Beacon Pointe Advisors held its Aspire Biopharma Warrant (ASBPW) position steady in Q2 2026 at 20,000 shares worth $400. The position accounts for ﹤0.01% of the portfolio, ranked #1915.

Beacon Pointe Advisors first reported a position in ASBPW in Q4 2025 and has held it in 3 quarters since. 27 funds tracked by Wall St. Rank hold ASBPW as of Q2 2026.

  • Beacon Pointe Advisors held 20,000 shares of Aspire Biopharma Warrant worth $400 as of Q2 2026.
  • Beacon Pointe Advisors left its Aspire Biopharma Warrant share count unchanged in Q2 2026.
  • Aspire Biopharma Warrant made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q2 2026, its #1915 holding.
  • Beacon Pointe Advisors first reported a position in Aspire Biopharma Warrant in Q4 2025 and has held it in 3 quarters since.
  • 27 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q2 2026.

Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.